Review Article

Exocrine Pancreatic Insufficiency in Diabetes Mellitus: A Complication of Diabetic Neuropathy or a Different Type of Diabetes?

Philip D. Hardt and Nils Ewald

Third Medical Department, University Hospital Giessen and Marburg, Giessen Site, Klinikstraße 33, 35392 Giessen, Germany

Correspondence should be addressed to Philip D. Hardt, philip.d.hardt@innere.med.uni-giessen.de

Received 27 March 2011; Accepted 25 May 2011

Academic Editor: Stavros Liatis

Copyright © 2011 P. D. Hardt and N. Ewald. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pancreatic exocrine insufficiency is a frequently observed phenomenon in type 1 and type 2 diabetes mellitus. Alterations of exocrine pancreatic morphology can also be found frequently in diabetic patients. Several hypotheses try to explain these findings, including lack of insulin as a trophic factor for exocrine tissue, changes in secretion and/or action of other islet hormones, and autoimmunity against common endocrine and exocrine antigens. Another explanation might be that diabetes mellitus could also be a consequence of underlying pancreatic diseases (e.g., chronic pancreatitis). Another pathophysiological concept proposes the functional and morphological alterations as a consequence of diabetic neuropathy. This paper discusses the currently available studies on this subject and tries to provide an overview of the current concepts of exocrine pancreatic insufficiency in diabetes mellitus.

1. Introduction

Decades ago research groups interested in the pancreas demonstrated that pancreatic exocrine insufficiency (PEI) is present in a considerable percentage of patients with diabetes mellitus. These early studies were performed by direct pancreatic function tests (e.g., secretin-pancreozymin test). PEI was demonstrated not only in about 50% of patients with insulin-dependent diabetes (IDDM) but also in 30–50% of non-insulin-dependent diabetes (NIDDM) [1–6]. Apart from these functional studies it was also observed that pancreas morphology is altered in many patients with diabetes mellitus. In IDDM the weight of pancreata was reduced as compared to healthy controls [7, 8] and there were histological aspects of pancreatic atrophy [9]. Before the introduction of imaging techniques such as ultrasound, CT, and MRI, morphological studies of the pancreas in vivo were difficult. Therefore the collection of data was limited to very small numbers of patients.

While in most of the discussions and comments the finding of altered pancreatic function and morphology was interpreted as a complication of diabetes mellitus, some scientists suggested that a high percentage of (previously not diagnosed) pancreatic diabetes might be a better explanation [2]. However, early studies on pancreatic function in diabetes were also limited to a rather small number of patients. This was due to the invasive nature of these test procedures including tube application into the duodenum and continuous aspiration of duodenal secretion for several hours.

In the last two decades of the 20th century indirect pancreatic function test became available. Especially the measurement of fecal elastase 1 concentrations (FECs) that can easily be performed in any setting proved rather good sensitivity and specificity [10–14]. Using these new indirect tests, the prevalence of PEI in diabetes mellitus could be demonstrated to be as high as in the earlier studies: nearly every second IDDM patient and one out of three NIDDM patient shows PEI [15–19]. The introduction of ultrasound, CT, and MRI did facilitate the investigation of pancreas morphology in vivo resulting in new research activity in the field.
The features of modern diagnostic techniques of pancreatic function and morphology allowed the investigation of large patient cohorts. Therefore the reasons for PEI and morphological changes in diabetes can now be interpreted on a more solid data base.

In the present paper the relevant literature in this context is reviewed and discussed. If the thesis of a relevant percentage of pancreatic diabetes cases proves true, this will have major impact on our diagnostic and therapeutic strategies.

2. Material and Methods

A Medline-search was performed (March 14th, 2011) using the following search terms: (a) diabetes mellitus and exocrine pancreatic insufficiency (PEI); (b) diabetes mellitus and elastase 1; (c) diabetes mellitus and pancreatitis; (d) diabetes mellitus and exocrine pancreatic function; (e) pancreas morphology and diabetes.

The search terms revealed the following number of quotations: (a) diabetes mellitus and exocrine pancreatic insufficiency (PEI): 279; (b) diabetes mellitus and elastase 1: 109; (c) diabetes mellitus and pancreatitis: 2321; (d) diabetes mellitus and exocrine pancreatic function, 1060; (e) pancreas morphology and diabetes: 9902.

Most of the papers addressed problems that are not directly related to the interest of the present review, for example diabetes and pancreatic cancer or pancreas/islet transplantation in diabetes mellitus. These were not further evaluated. The remaining articles were checked for the prevalence of PEI in diabetes mellitus, the prevalence of pancreatic diabetes (type 3c), morphological changes of the pancreas in diabetes mellitus, and the different hypotheses discussed in the context.

3. Results and Discussion

3.1. Pancreatic Exocrine Function in Diabetes Mellitus. Before the introduction of indirect function tests several studies have been performed using direct methods. Table 1 shows the results reported in these. On average, PEI was reported in 52.4% (18–100%) of patients with diabetes mellitus. PEI was reported more often in patients with IDDM. However, in some of the studies it was observed equally often in NIDDM. In Table 2 the results of studies using indirect function tests are shown. On average 51% (26–74%) of patients with IDDM and 32% (28–36%) of patients with NIDDM showed abnormal exocrine function. While fecal elastase 1 concentrations (FECs) are considered a diagnostic tool for pancreatic function of unknown direct relevance for the clinical situation in terms of maldigestion and associated symptoms, it has also been shown in the meantime that in fact steatorrhea can be detected in 60% of patients with diabetes mellitus and reduced FEC [26]. In another previous study it was demonstrated that in 74% of patients classified as type 1 diabetes mellitus steatorrhea was present and steatorrhea correlated inversely with FEC concentrations [27]. While one follow-up study in only 20 patients claimed that a progression of PEI is rare in diabetes mellitus [28], it must be concluded from the information presently available that in patients with diabetes mellitus PEI is not only very frequent in terms of pathological function tests but also in terms of fat maldigestion. This finding might explain abdominal symptoms in patients with diabetes mellitus. Qualitative malnutrition (fat soluble vitamins) must also be considered. Most interestingly, the incretin action might be altered in patients with steatorrhea [29] as the secretion of incretins depends on the presence of digestive products inside the digestive tract [30].

3.2. Pancreatic Exocrine Morphology in Diabetes Mellitus. Autopsy studies and studies on pancreas histology showed marked changes in the exocrine gland in patients with diabetes mellitus as compared to nondiabetic controls. Blumenthal reported signs of chronic inflammatory changes of the exocrine pancreas in 11.2% of patients with diabetes mellitus as compared to 5.3% in nondiabetic patients [31]. In another autopsy study Olsen reported the percentage of exocrine pancreatic atrophy in diabetic patients to be 19% compared to 7% in controls [32]. In patients with long-lasting type 1 diabetes mellitus a reduced weight of the gland was reported [7, 8]. It was also observed that in IDDM patients there is histological evidence of exocrine pancreas atrophy [7, 9]. Even within only 24 hours after the diagnosis of type 1 diabetes mellitus, severe atrophy of exocrine tissue around beta cells without remaining insulin activity could be found while around beta cells with remaining insulin content no acinar atrophy could be observed [33]. Rahier et al. showed a clear reduction of weight in the glucagon-rich lobe, but no atrophy in the pancreatic-polypeptide-rich lobe despite the lack of beta cells (and therefore the lack of insulin) [34]. In clinical medicine changes of pancreatic duct morphology in patients with diabetes mellitus similar to the changes observed in chronic pancreatitis were observed at ERCP procedures [35, 36].

With the introduction of the abdominal ultrasound as a diagnostic tool, the investigation of the pancreas became easier. There are several studies reporting a reduced size of the pancreas in patients with diabetes mellitus. Compared to sex- and age-matched controls the pancreata of children and adolescents with type 1 diabetes mellitus appeared clearly smaller [37]. Similar ultrasound changes were demonstrated in adults with type 1 and type 2 diabetes mellitus [38] and by use of CT and MRI technology [39, 40].

3.3. Hypothesis Explaining Pancreatic Damage in Patients with Diabetes Mellitus

3.3.1. Insulin as a Trophic Factor for Exocrine Tissue. In the second half of the last century it was shown that insulin acts as a trophic factor on acinar tissue [41]. There is a kind of portal vessel system supplying acinar cells directly with blood from nearby islets. Acinar cells located closely to these vessels are bigger and produce more enzymes than those located more distant [42]. But insulin is not only a local trophic factor, it also increases the enzyme output from cultivated islets [43]. In rats with glucose-stimulated insulin secretion the amount of total amylase and protein...
Table 1: Results of direct pancreatic function tests in patients with diabetes mellitus.

| Author              | Year | Subjects/diabetes type | Methods                                      | Results                                      |
|---------------------|------|------------------------|----------------------------------------------|----------------------------------------------|
| Pollard et al. [1]  | 1943 | 13                     | Amylase and lipase after pancreaticozymin-secretin stimulation | 62% reduced                                  |
| Chey et al. [2]     | 1963 | 50 diabetic patients; 13 juvenile type | Amylase and lipase after pancreaticozymin-secretin stimulation | Low amylase output in diabetes: 36%; in juvenile diabetes: 77% |
| Vaccia et al. [3]   | 1964 | 55 diabetic patients (22 insulin treated) | Diastase and bicarbonate after secretin stimulation; fecal fat | 73% abnormal; correlation with age, no correlation with fecal fat |
| Frier et al. [4]    | 1976 | 20 IDDM, 7 NIDDM, 13 controls | Stimulation with iv secretin and CCK-PZ | PEI: 80% IDDM; correlation with diabetes duration |
| Harano et al. [20]  | 1978 | 53 NIDDM, 4 IDDM, 18 controls | Secretin-pancreozymin test | Diabetes: 69% deficient enzyme output; correlation with diabetes control |
| Lankisch et al. [5] | 1982 | 53 IDDM | Secretin-pancreozymin test | Diabetes: 43% impaired function |
| Bretzke et al. [21] | 1984 | 60 insulin-treated type 2 diabetic patients | Secretin-pancreozymin test | Diabetes: 27% “mild PEI” |
| El Newihi et al. [22]| 1988 | 10 type 2 diabetic patients with diarrhea and neuropathy | Secretin and CCK test | Enzyme and bicarbonate reduction in all subjects |

Table 2: Results of indirect pancreatic function tests in patients with diabetes mellitus.

| Author               | Year | Subjects/diabetes type | Methods | Results |
|----------------------|------|------------------------|---------|---------|
| Hardt and Kloer [23] | 1998 | 128 type 1+2           | Fecal chymotrypsin | 45% <6 U/I |
|                      |      |                        | Fecal elastase 1 | 46% <200 μg/g |
| Hardt et al. [15]    | 2000 | 39 type 1              | Fecal elastase 1 | 74% <200 μg/g |
|                      |      | 77 type 2              | Fecal elastase 1 | 36% <200 μg/g |
| Icks et al. [18]     | 2001 | 112 type 1             | Fecal elastase 1 | 54.5% <200 μg/g |
| Rathmann et al. [17] | 2001 | 544 type 2             | Fecal elastase 1 | 30.3% <200 μg/g |
|                      |      | 323 type 1             | Fecal elastase 1 | 51% <200 μg/g |
|                      |      | 697 type 2             | Fecal elastase 1 | 35% <200 μg/g |
| Hardt et al. [16]    | 2003 | 42 type 1+2            | Fecal elastase 1 | 36% <200 μg/g |
| Nunes et al. [24]    | 2003 | 32 type 2              | Fecal elastase 1 | 28% <200 μg/g |
| Yilmaztepe et al. [25]| 2005| 66 type 1              | Fecal elastase 1 | 26% <200 μg/g |
| Cavalot et al. [19]  | 2004 |                        |         |         |

In conclusion the concept of a lack of local trophic insulin action might explain some of the phenomena observed; however it cannot explain the whole phenomenon.

3.3.2. Changes in Secretion/Action of Other Islet Hormones.
Apart from the changes in insulin secretion or action, other islet cell hormones are also known to act differently in patients with diabetes mellitus as compared to healthy controls. Some of them play an important role in the regulation of digestive and metabolic functions and therefore they might also lead to a dysregulation of the exocrine pancreatic function [45]. As a consequence atrophy might result. A persisting elevation of glucagon levels as observed in some diabetic patients has been suggested to contribute to exocrine damage and dysfunction [46, 47]. Somatostatin is a relevant regulator of exocrine function [48], and elevated levels, as described in streptozotocin-induced diabetes mellitus, have been shown to reduce exocrine pancreatic function [49]. While changes in glucagon and somatostatin secretion might also contribute to exocrine damage in some
of the patients with diabetes mellitus, they also do not fully explain the phenomena described in detail above. Some of the studies were only performed in animal models, and, more importantly, the patterns of secretory changes differ in type 1 and type 2 diabetes mellitus.

3.3.3. Autoimmunity. Autoimmune pancreatitis has gained more attention previously. In the different types of the disease that have been described an involvement of both, exocrine and endocrine tissue, is very frequent. Diabetes mellitus associated with autoimmune pancreatitis can be treated by steroids, and it can even be cured if the autoimmune attack can be stopped [50, 51]. Apart from these cases exocrine antigens might also play a role in the induction of autoimmunity against beta cells in the absence of classical autoimmune diabetes. Some decades ago it has been demonstrated mainly from Japanese scientists that in some subtypes of diabetes mellitus antibodies are present which are directed against exocrine antigens. Kobayashi et al. described antibodies against pancreatic cytokeratin in 39% of recent onset patients classified as type 1 diabetes mellitus and in 20% of their relatives. In type 2 diabetes mellitus patients only 0.9% had relevant antibody titers. The authors suggested that the ultrastructure of exocrine tissue might be involved in the pathogenesis of type 1 diabetes mellitus [52]. Another antibody against exocrine tissue (BSDL) was found in 73.5% of patients at diagnosis of type 1 diabetes mellitus [53]. Imagawa et al. even suggested the introduction of a new diabetes type: patients with rapid loss of insulin secretion but without the presence of islet- or insulin-associated autoimmunity. On histological samples their patients displayed a marked inflammation in the exocrine tissue with elevated levels of pancreatic enzymes [54]. In another study antibodies against lactoferrin or carbonic anhydrase (both directed against exocrine targets) were present in 77% of patients classified as type 1 diabetes mellitus [55].

While the quantitative input of autoimmune pancreatitis associated with diabetes mellitus surely is rather small, the possible relevance of exocrine antigens in the pathogenesis of autoimmune diabetes deserves further attention.

3.3.4. Diabetes Mellitus as a Consequence of Underlying Pancreatic Diseases. While PEI might be induced by diabetes mellitus, it could as well be the other way around as it has been proposed as early as 1963 by Chey et al. [2]. Different pancreatic diseases are known to induce diabetes mellitus, including different types of pancreatitis, pancreatic carcinoma, cystic fibrosis, and hemochromatosis. However, these diseases are believed to contribute to the burden of diabetes mellitus in only about 1% of all cases [56, 57]. The possibility that the prevalence of pancreatic diabetes might well be much higher than 1% has been discussed in detail elsewhere [58] and will not be issue of the present paper.

Additionally to those hypotheses explaining pancreatic damage in patients with diabetes mellitus, pancreatic exocrine insufficiency might also be interpreted as a complication of diabetic neuropathy.

3.4. Pancreatic Exocrine Insufficiency as a Complication of Diabetic Neuropathy. Diabetic neuropathy (DN) is a complication of diabetes mellitus that might occur in the time course of the disease. While the prevalence of DN is about 4–7.5% at the time of diagnosis, it is observed in 15–50% of the patients after 20–25 years of diabetes mellitus [59]. Autonomic neuropathy can affect not only the cardiovascular system, but also different functions of the digestive tract. Gastrointestinal motor disorders, for example, gastroparesis, diabetic diarrhea, diabetic obstipation, and fecal incontinence as a complication of diabetes mellitus have been described in detail [60]. It seems obvious that some of the gastrointestinal symptoms that occur in patients with diabetes mellitus are caused by DN. On the other hand, diabetic diarrhea and bloating might arise from the exocrine insufficiency that is probably even more common than DN in patients with diabetes mellitus. Since the regulation of enzyme synthesis and secretion does not only depend on gastrointestinal hormones produced somewhere else but also on local neurons and their signals, exocrine insufficiency itself could be caused by DN. This possibility has been taken into consideration in several studies dating back to the last century. However, one main argument against the assumption that DN might cause PEI was the lack of correlation between the duration of diabetes mellitus and the finding of exocrine insufficiency [2, 3]. However, more recently two studies [19, 61] demonstrated a significant increase of PEI in the time course of diabetes mellitus. Cavalot had shown earlier that fecal elastase 1 levels are correlated with the remaining C-peptide levels in 37 patients with type 1 diabetes mellitus suggesting that the remaining insulin presence might be of relevance for exocrine pancreatic function. While this explanation was in contrast to most other publications at that time, the finding could also be interpreted differently: C-peptide levels are known to decrease by time in type 1 diabetes mellitus while the probability of DN does increase. In fact, there was also a weak inverse correlation between diabetes duration and PEI despite the small number of individuals included in the study [26]. A more recent study by Ewald et al. involved data from 307 patients with different types of diabetes. Diabetes duration was inversely correlated with fecal elastase 1 concentrations ($P = 0.004$), and there was also a correlation between C-peptide levels and FEC ($P < 0.001$) [61]. The fact that earlier studies missed to show a correlation between disease duration and exocrine pancreatic function might be explained by smaller patient numbers that had been included into these studies.

Mechanisms linking exocrine pancreatic insufficiency might be the impairment of enteropancreatic reflexes or changes in gastrointestinal peptides. Enteropancreatic reflexes for example are known to play an important role in pancreatic responses, and according to older data as much as 50% of the exocrine pancreatic response to a meal may be mediated by enteropancreatic reflexes [22]. Interruption of the enteropancreatic reflexes by an autonomic neuropathy might therefore severely impair exocrine pancreatic function. Yet data on this topic is scarce and further research is strongly encouraged.
4. Conclusion

In the light of the literature reviewed for this paper there is clear evidence that both pancreas morphology and exocrine pancreatic function are very frequently and severely altered in patients with different types of diabetes mellitus. Several hypotheses have been discussed to explain these findings. A high prevalence of diabetes caused by pancreatic diseases (including autoimmune pancreatitis) appears unlikely because pancreatic diseases themselves have a low prevalence according to the clinical literature. Lack of local trophic insulin action causing acinar atrophy does not explain the fact that most patients with type 1 diabetes mellitus have no signs of exocrine changes. If local insulin deficiency was the main issue, an exocrine involvement should be expected in all signs of exocrine changes. If local insulin deficiency was the fact that most patients with type 1 diabetes mellitus have no insulin action causing acinar atrophy does not explain the because pancreatic diseases themselves have a low prevalence eas (including autoimmune pancreatitis) appears unlikely hypotheses have been discussed to explain these findings.

References

[1] H. M. Pollard, L. Miller, and W. A. Brewer, “External secretion of the pancreas and diabetes (study of secretin test),” The American Journal of Digestive Diseases, vol. 10, no. 1, pp. 20–23, 1943.
[2] W. Y. Chey, H. Shay, and C. R. Shuman, “External pancreatic secretion in diabetes mellitus,” Annals of Internal Medicine, vol. 59, pp. 812–821, 1963.
[3] J. B. Vacca, W. J. Henke, and W. A. Knight, “The exocrine pancreas in diabetes mellitus,” Annals of Internal Medicine, vol. 61, pp. 242–247, 1964.
[4] B. M. Frier, J. B. Saunders, K. G. Wormsley, and I. A. D. Boucher, “Exocrine pancreatic function in juvenile-onset diabetes mellitus,” Gut, vol. 17, no. 9, pp. 685–691, 1976.
[5] P. G. Lankisch, G. Manthey, J. Otto, M. Talaulicar, B. Willms, and W. Creutzfeldt, “Exocrine pancreatic function in insulin-dependent diabetes mellitus,” Digestion, vol. 25, pp. 210–216, 1982.
[6] G. Gröger and P. Layer, “Exocrine pancreatic function in diabetes mellitus,” The European Journal of Gastroenterology and Hepatology, vol. 7, pp. 740–746, 1995.
[7] W. Gepts, “Pathologic anatomy of the pancreas in juvenile diabetes mellitus,” Diabetes, vol. 14, no. 10, pp. 619–633, 1965.
[8] N. MacLean and R. F. Ogilvie, “Observations on the pancreatic islet tissue of young diabetic subjects,” Diabetes, vol. 8, no. 2, pp. 83–91, 1959.
[9] P. M. Le Compte and W. Gepts, “The pathology of juvenile diabetes,” in The Diabetic Pancreas, B. W. Volk and K. F. Wellmann, Eds., pp. 325–363, Plenum Press, New York, NY, USA, 1977.
[10] U. Scheevers-Borchel, H. Scheevers, R. Arnold, P. Fischer, and A. Szegoleit, “Pankreatische Elastase 1: Parameter für die chronische und akute Pankreatitis,” Laboratoriumsmedizin, vol. 16, no. 12, pp. 427–432, 1992.
[11] A. Szegoleit, E. Krause, H. U. Klör, L. Kanacher, and D. Linder, “Elastase 1 and chymotrypsin B in pancreatic juice and feces,” Clinical Biochemistry, vol. 22, no. 2, pp. 85–89, 1989.
[12] G. Löser, A. Möllgaard, and U. R. Folsch, “Fecal elastase 1: a novel, highly sensitive and specific tubeless pancreatic function test,” Gut, vol. 39, no. 4, pp. 580–586, 1996.
[13] J. Stein, Z. Spirchez, B. Lembcke, and W. F. Caspary, “Investigations to the diagnostic value of elastase 1 test,” Zeitschrift für Gastroenterologie, supplement 1, pp. 122–129, 1997.
[14] J. E. Dominguez-Munoz, C. Hieronymus, T. Sauerbruch, and P. Malfertheiner, “Fecal elastase test: evaluation of a new noninvasive pancreatic function test,” The American Journal of Gastroenterology, vol. 90, no. 10, pp. 1834–1837, 1995.
[15] P. D. Hardt, A. Krauss, L. Bretz et al., “Pancreatic exocrine function in patients with type-1 and type-2 diabetes mellitus,” Acta Diabetologica, vol. 37, no. 3, pp. 105–110, 2000.
[16] P. D. Hardt, A. Hauenschl, J. Nalop et al., “High prevalence of exocrine pancreatic insufficiency in diabetes mellitus. A multicenter study screening fecal elastase 1 concentrations in 1,021 diabetic patients,” Pancreatology, vol. 3, no. 5, pp. 395–402, 2003.
[17] W. Rathmann, B. Haastert, A. Icks et al., “Low fecal elastase 1 concentrations in type 2 diabetes,” Scandinavian Journal of Gastroenterology, vol. 36, pp. 1056–1061, 2001.
[18] A. Icks, B. Haastert, G. Giani, and W. Rathmann, “Low fecal elastase-1 in type 1 diabetes mellitus,” Zeitschrift für Gastroenterologie, vol. 39, no. 10, pp. 823–830, 2001.
[19] F. Cavalot, K. Bonomo, P. Perna et al., “Pancreatic elastase-1 in stools, a marker of exocrine pancreatic function, correlates with both residual β-cell secretion and metabolic control in type 1 diabetic subjects,” Diabetes Care, vol. 27, no. 8, pp. 2052–2054, 2004.
[20] Y. Harano, C. I. Kim, M. Kang et al., “External pancreatic dysfunction associated with diabetes mellitus,” Journal of Laboratory and Clinical Medicine, vol. 91, pp. 780–790, 1978.
[21] G. Bretzke, “Diabetes mellitus und exokrine Pankreas funktion,” Zeitschrift für die Gesamte Innere Medizin und Ihre Grenzgebiete, vol. 39, no. 16, pp. 388–390, 1984.
[22] H. El Newihi, C. P. Dooley, C. Saad, J. Staples, A. Zeidler, and J. E. Valenzuela, “Impaired exocrine pancreatic function in diabetics with diarrhea and peripheral neuropathy,” Digestive Diseases and Sciences, vol. 35, no. 6, pp. 705–710, 1988.
[23] P. D. Hardt and H. U. Kloor, “Diabetes mellitus and exocrine pancreatic disease,” in Pancreatic Disease, C. D. Johnson and C. W. Imrie, Eds., pp. 235–241, Springer, London, UK, 2nd edition, 1998.
[24] A. C. Nunes, J. M. Pontes, A. Rosa, L. Gomes, M. Carvalheiro, and D. Freitas, “Screening for pancreatic exocrine insufficiency in patients with diabetes mellitus,” The American Journal of Gastroenterology, vol. 98, no. 12, pp. 2672–2675, 2003.
[25] A. Yilmaztepe, E. Ulukaya, C. Ersoy, M. Yilmaz, and H. A. Tokullugil, “Investigation of fecal pancreatic elastase-1
levels in type 2 diabetic patients,” *The Turkish Journal of Gastroenterology*, vol. 16, no. 2, pp. 75–80, 2005.

[26] P. D. Hardt, A. Hauenschild, C. Jaeger, J. Teichmann, R. G. Bretzel, and H. U. Kloer, “High prevalence of steatorrhea in 101 diabetic patients likely to suffer from exocrine pancreatic insufficiency according to low fecal elastase 1 concentrations: a prospective multicenter study,” *Digestive Diseases and Sciences*, vol. 48, no. 9, pp. 1688–1692, 2003.

[27] F. Cavalot, K. Bonomo, E. Fiora et al., “Does pancreatic elastase-1 in stools predict steatorrhea in type 1 diabetes?” *Diabetes Care*, vol. 29, no. 3, pp. 719–721, 2006.

[28] W. Creutzfeldt, D. Gleichmann, J. Otto, F. Stöckmann, P. Maisonneuve, and P. G. Lankisch, “Follow-up of exocrine pancreatic function in type-1 diabetes mellitus,” *Digestion*, vol. 72, no. 2-3, pp. 71–75, 2005.

[29] R. Ebert and W. Creutzfeldt, “Reversal of impaired GIP and insulin secretion in patients with pancreatic steatorrhea following enzyme substitution,” *Diabetologia*, vol. 19, no. 3, pp. 198–204, 1980.

[30] C. Herrmann, R. Göke, H. C. Fehmann, G. Richter, R. Arnold, and B. Göke, “Glucagon-like peptide 1 and glucose-dependent insulin-releasing polypeptide secretion in response to nutrients,” *Digestion*, vol. 56, no. 2, pp. 117–126, 1995.

[31] H. T. Blumenthal, J. G. Probsthofer, and A. W. Berns, “Interrelationship of diabetes mellitus and pancreatitis,” *Archives of Surgery*, vol. 87, pp. 844–850, 1963.

[32] R. S. Olsen, “The incidence and clinical relevance of chronic inflammation in the pancreas in autopsy material,” *Acta Pathologica et Microbiologica Scandinavica—Section A*, vol. 86, no. 5, pp. 361–364, 1978.

[33] A. K. Foulis and J. A. Stewart, “The pancreas in recent-onset type 1 (insulin-dependent) diabetes mellitus: insulin content of islets, insulitis and associated changes in the exocrine acinar tissue,” *Diabetologia*, vol. 26, no. 6, pp. 456–461, 1984.

[34] J. Rahier, R. M. Goebbels, and J. C. Henquin, “Cellular composition of the human diabetic pancreas,” *Diabetologia*, vol. 24, no. 5, pp. 366–371, 1983.

[35] K. Nakashishi, T. Kobayashi, H. Miyashita et al., “Exocrine pancreatic ductograms in insulin-dependent diabetes mellitus,” *The American Journal of Gastroenterology*, vol. 89, no. 5, pp. 762–766, 1994.

[36] P. D. Hardt, A. Killinger, J. Nalop, H. Schnell-Kretschmer, T. Zekorn, and H. U. Klör, “Chronic pancreatitis and diabetes mellitus. A retrospective analysis of 156 ERCP investigations in patients with insulin-dependent and non-insulin-dependent diabetes mellitus,” *Pancreatology*, vol. 2, no. 1, pp. 30–32, 2002.

[37] F. Chiarelli, A. Verrotti, E. Altolelli, A. Blasetti, and G. Morgese, “Size of the pancreas in type I diabetic children and adolescents,” *Diabetes Care*, vol. 18, no. 11, pp. 1505–1506, 1995.

[38] V. Fonseca, L. A. Berger, A. G. Beckett, and P. Dandona, “Size of pancreas in diabetes mellitus: a study based on ultrasound,” *The British Medical Journal—Clinical Research*, vol. 291, no. 6504, pp. 1240–1241, 1985.

[39] J. P. Gilbeau, V. Poncelet, E. Libon, G. Derue, and F. R. Heller, “The density, contour and thickness of the pancreas in diabetics,” *The American Journal of Roentgenology*, vol. 159, no. 3, pp. 527–531, 1992.

[40] M. Bilgin, N. C. Balci, A. J. Momtahan, Y. Bilgin, H. U. Klör, and W. S. Rau, “MRI and MRCP findings of the pancreas in patients with diabetes mellitus: compared analysis with pancreatic exocrine function determined by fecal elastase 1,” *Journal of Clinical Gastroenterology*, vol. 43, no. 2, pp. 165–170, 2009.

[41] J. A. Williams and I. D. Goldfine, “The insulin-pancreatic acinar axis,” *Diabetes*, vol. 34, no. 10, pp. 980–986, 1985.

[42] G. Adler and H. F. Kern, “Regulation of exocrine pancreatic secretory process by insulin,” *Hormone and Metabolic Research*, vol. 7, no. 4, pp. 290–296, 1975.

[43] M. Korc, D. Owerbach, C. Quinto, and W. J. Rutter, “Pancreatic islet-acinar cell interaction: amylase messenger RNA levels are determined by insulin,” *Science*, vol. 213, no. 4505, pp. 351–353, 1981.

[44] M. Lühr and G. Klöppel, “Residual insulin positivity and pancreatic atrophy in relation to duration of chronic type i (insulin dependent) diabetes mellitus and microangiopathy,” *Diabetologia*, vol. 30, no. 10, pp. 757–762, 1987.

[45] J. R. Henderson, “Why are the islets of Langerhans?” *The Lancet*, vol. 2, no. 7618, pp. 469–470, 1969.

[46] R. H. Unger, E. Aguilar-Parada, W. A. Müller, and A. M. Eisenbraut, “Studies of pancreatic alpha cell function in normal and diabetic subjects,” *The Journal of Clinical Investigation*, vol. 49, no. 4, pp. 837–848, 1970.

[47] W. P. Dyck, J. Rudick, B. Hoexter, and H. D. Janowitz, “Influence of glucagon on pancreatic exocrine secretion,” *Gastroenterology*, vol. 56, no. 3, pp. 531–537, 1969.

[48] K. Gyr, C. Beglinger, E. Kohler, U. Trautzl, U. Keller, and S. R. Bloom, “Circulating somatostatin. Physiological regulator of pancreatic function?” *The Journal of Clinical Investigation*, vol. 79, pp. 1595–1600, 1987.

[49] J. Y. Patel and G. C. Weir, “Increased somatostatin content of islets from streptozotocin-diabetic rats,” *Clinical Endocrinology*, vol. 5, no. 2, pp. 191–194, 1976.

[50] S. Tanaka, T. Kobayashi, K. Nakanishi et al., “Corticosteroid-responsive diabetes mellitus associated with autoimmune pancreatitis: pathological examinations of the endocrine and exocrine pancreas,” *Annals of the New York Academy of Sciences*, vol. 958, pp. 152–159, 2002.

[51] G. Klöppel, I. Lüttges, M. Lühr, G. Zamboni, and D. Longnecker, “Autoimmune pancreatitis: pathological, clinical and immunological features,” *Pancras*, vol. 27, no. 1, pp. 14–19, 2003.

[52] T. Kobayashi, K. Nakanishi, H. Kajio et al., “Pancreatic cytokeratin: an antigen of pancreatic exocrine cell autoantibodies in type 1 (insulin-dependent) diabetes mellitus,” *Diabetologia*, vol. 33, no. 6, pp. 363–370, 1990.

[53] L. Panicò, E. Mas, C. Thivolet, and D. Lombardo, “Circulating antibodies against an exocrine pancreatic enzyme in type 1 diabetes,” *Diabetes*, vol. 48, no. 12, pp. 2316–2323, 1999.

[54] A. Imagawa, T. Hanafusa, J. I. Miyagawa, and Y. Matsuzawa, “A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies,” *The New England Journal of Medicine*, vol. 342, no. 5, pp. 301–307, 2000.

[55] T. Taniguchi, K. Okazaki, M. Okamoto et al., “High prevalence of autoantibodies against carbonic anhydrase II and lactoferrin in type 1 diabetes: concept of autoimmune exocrinopathy and endocrinopathy of the pancreas,” *Pancreas*, vol. 27, no. 1, pp. 26–30, 2003.

[56] O. Günther, *Zur Ätiologie des Diabetes Mellitus*, Akademie-Verlag, Berlin, Germany, 1961.

[57] K. G. M. Alberdi, “Diabetes secondary to pancreatopathy: an example of brittle diabetes,” in *Diabetes Secondary to Pancreatopathy. International Congress Series 762*, A. Tiengo, K. G. M. Alberdi, S. DelPrato, and M. Vranic, Eds., pp. 7–20, Excerpta Medica, Amsterdam, The Netherlands, 1988.
[58] P. D. Hardt, M. D. Brendel, H. U. Kloer, and R. G. Bretzel, “Is pancreatic diabetes (type 3c diabetes) underdiagnosed and misdiagnosed?” *Diabetes Care*, vol. 31, pp. S165–S169, 2008.

[59] J. Pirart, “Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973,” *Diabetes Care*, vol. 1, no. 4, pp. 252–263, 1978.

[60] F. Strian and M. Halsbeck, “Neurologische Erkrankungen,” in *Diabetologie in Klinik und Praxis*, H. Mehnert, E. Standl, K. H. Usadel, and H. U. Häring, Eds., pp. 802–805, Thieme, Stuttgart, Germany, 2003.

[61] N. Ewald, A. Raspe, C. Kaufmann, R. G. Bretzel, H. U. Kloer, and P. D. Hardt, “Determinants of exocrine pancreatic function as measured by fecal elastase-1 concentrations (FEC) in patients with diabetes mellitus,” *The European Journal of Medical Research*, vol. 14, no. 3, pp. 118–122, 2009.

[62] M. Vesterhus, H. Ræder, H. Aurlien et al., “Neurological features and enzyme therapy in patients with endocrine and exocrine pancreas dysfunction due to CEL mutations,” *Diabetes Care*, vol. 31, no. 9, pp. 1738–1740, 2008.

[63] G. Davidai, T. Zakaria, R. Goldstein, A. Gilai, and S. Freier, “Hypovitaminosis E induced neuropathy in exocrine pancreatic failure,” *Archives of Disease in Childhood*, vol. 61, pp. 901–903, 1986.